Glow Peptide Stack benefits and uses

How to read Glow benefit claims

Glow is promoted mainly for skin, but no published study has tested the blend, so every claimed benefit is borrowed from research on one ingredient at a time.¹ That research spans very different levels of evidence:

Two cautions apply across the GHK-Cu literature. First, about 35% of the primary research counted in a 2026 systematic review includes Loren Pickart or Anna Margolina of Skin Biology Inc. as an author.² Pickart first isolated the peptide and held commercial interests in the field for decades.² The review calls this group's work scientifically substantive but says the concentration of authorship limits the independence of the evidence.² Second, the 71- and 41-woman cream studies are known only from 2002 dermatology meeting proceedings cited in the pair's 2018 review.⁴

Skin

• Face cream, 71 women. A GHK-Cu cream used for 12 weeks on photoaged skin increased skin density and thickness. It also reduced laxity, fine lines and wrinkle depth.⁴
• Eye cream, 41 women. A GHK-Cu eye cream used for 12 weeks performed better than placebo and a vitamin K cream.⁴
• Thigh skin collagen. In skin biopsies after creams were applied to the thighs, collagen production rose in 70% of women using GHK-Cu, versus 50% with vitamin C cream and 40% with retinoic acid. The review does not give the number of participants.¹³
• Wrinkle serum. In a randomized, double-blind 8-week trial in women, of unstated size, GHK-Cu in a nano-lipid carrier produced a 31.6% reduction in wrinkle volume compared with Matrixyl 3000. Against the carrier serum alone, it cut wrinkle volume by 55.8% and depth by 32.8%.⁴
• After laser resurfacing. In a randomized study that 13 patients completed, GHK-Cu skin care did not speed the fading of redness. It gave no objective gain in wrinkles or skin quality, though users were more satisfied.¹⁴

In the lab, GHK-Cu raised collagen output by cultured fibroblasts and increased connective tissue in rat wound chambers.¹²¹⁵ A 2026 systematic review of 64 records still judged the human literature thin and fragmented.²

Hair

No published study has tested Glow on hair.¹ A lab study of human hair follicles kept in culture used AHK-Cu, a different copper peptide, not GHK-Cu; AHK-Cu lengthened the follicles.¹⁶ In 18 adults, a 2% GHK-Cu serum applied to one eyebrow twice daily for 12 weeks increased hair count. The placebo side showed no significant change, and the study was published as a conference poster.¹⁷⁶ A GHK complex with 5-aminolevulinic acid, not GHK-Cu, raised hair counts in 45 men with pattern hair loss over 6 months. Counts rose by 52.6 and 71.5 at two strengths, versus 9.6 with placebo.¹⁸

Wound, tendon and tissue repair

• Diabetic foot ulcers (GHK-Cu, people). In a multicenter, randomized, evaluator-blinded, placebo-controlled trial, a GHK-Cu gel with standard wound care raised median ulcer closure to 98.5%, versus 60.8% with vehicle. In ulcers treated right after debridement, infections occurred in 7%, versus 34% with vehicle.⁵ The abstract does not give the number of patients.
• Achilles tendon (TB-500 and BPC-157, rats). In 32 rats, both peptides raised maximum load to failure at 4 weeks, but only the TB-500 group differed significantly from controls. Combining the two gave no additional benefit over either alone.⁷
• Knee ligament graft (GHK-Cu, rats). Weekly joint injections improved graft healing in 72 rats, but the effect faded after treatment ended.⁸
• Gut, kidney and tendon (BPC-157, rodents). Pharmacology studies suggest BPC-157 prevents induced gut and cardiovascular lesions, protects the kidneys and promotes healing of cut tendons.¹⁹ FDA notes that its molecular targets are unidentified.¹⁹
• Skin wounds (TB-500's sequence, mice). Topical unacetylated LKKTETQ improved wound closure and collagen in aged mice, but FDA says this cannot be directly extrapolated to TB-500.²⁰ TB-500 itself showed no wound-healing effect in a cell study.²⁰
• Dry eye (thymosin beta-4, people). Eye drops of full-length thymosin beta-4, not TB-500, reduced ocular discomfort by 35.1% versus vehicle at day 56 in a trial of 9 people with severe dry eye.²¹

A 2026 orthopaedic review found no clinical data supporting GHK-Cu for musculoskeletal conditions.²²

Joints, muscle and recovery

• Knee pain (BPC-157, people). In a retrospective chart review at one Florida clinic, 16 patients were surveyed by phone. 11 of the 12 given BPC-157 knee injections reported significant improvement, as did 3 of the 4 who also received thymosin beta-4.⁹ A 2026 review cites significant methodological flaws and a lack of controls.²²
• BPC-157 overall. A 2026 systematic review found three human studies, 30 participants in all, and rated the certainty of evidence very low. It advised against clinical use outside regulated, high-quality trials.²³
• Muscle. No published human study links Glow or its ingredients to muscle repair.²³²⁰²² In mice exposed to cigarette smoke, GHK-Cu injections reduced muscle mass loss and weakness.¹⁰ A trial of BPC-157 for acute hamstring strain was recruiting in 2026.¹¹

What is not known

It is unknown whether the three peptides do anything together, because no published study has tested the blend.¹ FDA found no human studies of TB-500, and most human GHK-Cu trials used creams on the skin.²⁰²

Related reading: What is Glow Peptide Stack?, Glow Peptide Stack side effects and Glow Peptide Stack dosage. Goal overviews: Peptides and skin and hair and Peptides and healing and recovery. Ingredient profiles: What is GHK-Cu?, What is BPC-157? and What is TB-500?. The research vial: Glow Peptide Stack for sale.